REGULAR ARTICLE



The one-pot four-component eco-friendly synthesis of spirooxindoles in deep eutectic solvent

THOKCHOM JEETA DEVI, THOKCHOM PRASANTA SINGH and OKRAM MUKHERJEE SINGH*

Chemistry Department, Manipur University, Canchipur 795 003, Manipur, India E-mail: ok_mukherjee@yahoo.co.in Thokchom Jeeta Devi and Thokchom Prasanta Singh have equal contribution.

MS received 25 July 2019; revised 1 October 2019; accepted 4 October 2019

Abstract. An efficient and facile synthesis of spirooxindole derivatives bearing pyrano[2,3-*c*]pyrazole moiety has been achieved using deep eutectic solvent (DES) promoting a four-component reaction. The protocol avoids the use of costly and toxic catalysts and organic solvents which encounters many side effects on the environment and human beings. The simplicity and versatility of this eco-friendly green method is described.

Keywords. Deep eutectic solvent; spirooxindoles; eco-friendly; hydrazine; isatin.

1. Introduction

The chemistry of indole is one of the most exciting and challenging field for investigative works of synthetic and medicinal chemists.¹ The significant application of indole derivatives in pharmaceuticals, agrochemicals and organic electronics continues to inspire the tireless efforts of synthetic organic chemists since time immemorial.² Among the indole derivatives, the spirooxindole derivatives also occupy a special place in organic and medicinal chemistry since they exhibit diverse biological and pharmacological activities.^{3,4} Representative examples of spirooxindole, spirotryprostatin A and B, isolated from the fermentation broth of Aspergillus fumigatus, were found to completely inhibit the G2/M progression of cellular division in mammalian tsFT210 cells (Figure 1).⁵ In the field of synthetic therapeutic agents, compounds containing the spirooxindole core, SOID-8, analogue of spirotryprostatin B, have been described as having anticancer activity against Melanoma cells,⁶ while NITD609 is a promising novel drug for the treatment of malaria (Figure 1).^{7,8} In light of their unique structural features along with the important biological activities, spirooxindole derivatives have drawn considerable attention to synthetic chemists for their preparation.⁹ In spite of several reports on the synthesis of spirooxindole derivatives involving various application of catalysts and promoters such as β -cyclodextrin,¹⁰ piperidine,^{11,12} *L*-proline,¹³ ZrO₂,¹⁴ 4-DMAP,¹⁵ ionic liquid,^{16,17} CeO₂-NPs,¹⁸ dodecylbenzenesulphonic acid,¹⁹ Fe₃O₄ nanopartricles,²⁰ organometallic nanomagnetic,²¹ SBA-Pr-SO₃H,²² nanoclay,²³ and Fe₃O₄@SiO₂-SO₃H and Fe₃O₄@-SiO₂-NH^{2,24} the demand for effective and environmentally benign synthetic approaches to spirooxindole derivatives bearing pyrano[2,3-*c*]pyrazoles remains an immense interest to organic chemists.

The challenges in resources and environmental sustainability require more efficient and benign scientific technologies for chemical processes and the manufacture of products. Deep eutectic solvents (DESs) addresses such challenges by bridging as environmentally friendly and acceptable, due to their low vapor pressure, non-toxic properties, reusability, and cheapness.^{25,26} DESs are prepared as mixtures of two or more components, forming a eutectic with a melting point much lower than the starting

^{*}For correspondence

Electronic supplementary material: The online version of this article (https://doi.org/10.1007/s12039-019-1730-6) contains supplementary material, which is available to authorized users.



Figure 1. Examples of natural products and synthetic therapeutic agents containing a spiroxindole core.

components. The components of DES are biodegradable and approximately ten-fold less expensive as compared to ionic liquids. Among the DESs, choline chloride: urea-based DES has been successfully used for carboline synthesis,²⁷ coumarin synthesis,²⁸ lipasecatalyzed transesterifications,²⁹ syntheses of dihydropyrimidin-2(1H)-ones,³⁰ etc.

Thus, in continuation of our work in indole chemistry, $^{31-34}$ we are reporting an eco-friendly one-pot synthesis of spiro[indoline-3,4'-pyrano[2,3-*c*]pyrazole derivatives using DES-catalyzed four-component reaction of β -ketoesters, phenylhydrazines, malononitrile, and isatins (Scheme 1).

2. Experimental

All of the commercially available reagents and solvents were used without further purification. The chromatographic purification of compounds was carried out on silica gel (60–200 μ m). TLC analysis was performed on precoated (0.25 mm) glass supported silica gel plates (Kieselgel 60). All ¹H NMR and ¹³C NMR spectra were recorded on a Bruker-400 and 100.62 MHz, respectively using CDCl₃ as the solvent with tetramethylsilane (TMS) as an internal standard. The following abbreviations are used to describe peak patterns: s = singlet, d = doublet, t = triplet q = quartet, m = multiplet. All coupling constants (*J*) are given in Hz. FTIR spectra were recorded in FT/IR 410 spectrophotometer. Melting points were determined in



Scheme 1. Synthesis of spirooxindoles in DES.

open capillary tubes and are uncorrected using Buchi melting point apparatus.

2.1 Preparation of deep eutectic solvent

According to literature,²⁶ 50 mmol choline chloride and the required amount of urea were mixed as shown in Table 1, in a round flask and were heated to obtain a clear liquid as DES called urea:ChCl (Figure 2).

The FT-IR spectra of freshly prepared urea:ChCL (2:1) and the 1st and 2nd recycled urea:ChCl (2:1) were recorded in FT-IR Spectrophotometer (Perkin Elmer Spectrum-2). Figure 3 depicts the spectral analysis of bond frequencies for urea:ChCl which indicates a close resemblance with the corresponding peaks from the reported literature.³⁵ From the IR spectra of freshly prepared urea:ChCl Figure 3, the broad absorption bands at 3423 cm^{-1} and 3322 cm^{-1} indicates the stretching mode of $-NH_2$ (v_{as} NH₂ and v_{s} NH₂). The existence of board bands results from the formation of hydrogen bonding between urea and choline chloride. The hydrogen bonds formed may be represented as N-H.^{...}N-H, N-H.^{...}O-H, H-O.^{...}HO and O-H.^{...}N-H. Further, the presence of bending mode of -NH₂ (δ_s NH₂ and δ_{as} NH_2) is attributed by the values at 1653 cm⁻¹ and 1615 cm^{-1} . In addition, the bands at 1428 cm^{-1} and 949 cm^{-1} correspond to ρCH_3 and νCCO of ChCl, respectively. These clearly reveal that the structure of Ch⁺ in ChCl is not destroyed in Urea:ChCl system. On comparing the spectra of freshly prepared and recycles, similar peaks are obtained which support that the recycled urea:ChCl can be further used for various reaction system.

2.2 General procedure for the synthesis of spirooxindole derivatives (5a–5r)

A mixture of β -ketoester 1 (1 mmol), phenylhydrazine 2 (1 mmol), isatin 3 (1 mmol), active methylene compounds 4 (1 mmol), and Urea:ChCl (10 mol%, 5 mL) was stirred at room temperature for 10 min or until the completion of reaction as indicated by TLC. After completion of the reaction, the reaction mixture was poured to 25 mL water and extracted with 50 mL of ethyl acetate. The separated organic layer was dried over anhydrous Na₂SO₄, filtered and evaporated. Column chromatography was performed using 10% EtOAc in hexane as eluent to get the desired products, which were further recrystallized from warm ethanol to get pure compounds.

2.3 Spectral data of synthesized compounds

2.3a Entry-5a: 6'-Amino-3'-methyl-2-oxo-1'-phenyl-1'Hspiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'- carbonitrile: White solid (85%); M.p. 234–236 °C (exp), 238–240 °C (rep);¹² IR (KBr, v, cm⁻¹): 3369, 3154, 3031,

Entry	Solvent	Time (min)	Temp (°C)	Yield ^b (%)
1	Urea:ChCl (2:1)	5	r.t.	85
2	Urea:ChCl (2:1)	10	r.t.	90
3	Urea:ChCl (2:1)	30	r.t.	90
4	Urea:ChCl (2:1)	10	50	90
5	Urea:ChCl (2:1)	10	60	90
6	Urea:ChCl (2:1)	30	4	80
7	Malonic acid:ChCl: (1:1)	10	r.t.	80
8	Oxalic acid:ChCl (2:1)	30	r.t.	70
9	PTSA:ChCl (2:1)	30	r.t.	60
10	Glycerin:ChCl (2:1)	30	r.t	75
11	N/A	360	r.t	No reaction

 Table 1. Optimization of reaction condition^a.

^aReaction condition: methylacetoacetate **1a** (1 mmol), phenyl hydrazine **2a** (1 mmol), isatin **3a** (1 mmol) and malonitrile **4a** (1 mmol), DESs (5 mL).

^bIsolated yield of products.



Figure 2. (a) Deep eutectic solvent preparation from urea and ChCl in 2:1 ratio. (b) The FT-IR spectra of freshly prepared Urea:ChCl (2:1) and the 1st recycled and 2nd recycled Urea:ChCl (2:1).



Figure 3. Recycling studies of deep eutectic mixture of (urea:ChCl) in reaction of ethylacetoacetate 1a, phenyl hydrazine 2a, isatin 3a and malonitrile 4a.

2927, 2808, 2093, 1701, 1639, 1611, 1503, 1477, 1401, 1340, 1301, 1217, 1045, 926, 863, 821, 768, 624; ¹H NMR (400 MHz, CDCl₃): δ 10.71 (s, 1H), 7.89 (s, 1H), 7.66 (d,

J = 7.2 Hz, 1H), 7.38–7.35 (m, 2H), 7.34–7.21 (m, 4H), 7.12–7.04 (m, 2H), 6.92 (d, *J* = 8.0 Hz, 1H), 1.67 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 13.6, 48.8, 58.9, 110.1, 114.4, 119.1, 122.6, 124.8, 126.8, 127.6, 128.0, 129.4, 138.0, 142.5, 147.1, 153.1, 168.0, 177.6; EIMS (*m*/*z*): 369 (M⁺); Anal. calcd for C₂₁H₁₅N₅O₂: C, 68.28; H, 4.09; N, 18.96; O, 8.66. Found: C, 68.24; H, 4.12; N, 18.91; O, 8.63.

2.3b Entry-5b: 6'-Amino-2-oxo-1'-phenyl-3'-propyl-1'Hspiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'-carbonitrile: White solid (83%); M.p. 213–215 °C (exp), 211–213 °C (rep);¹² IR (KBr, v, cm⁻¹): 3520, 3354, 3305, 3179, 3069, 3031, 2952, 2921, 2862, 2201, 1705, 1653, 1595, 1522, 1468, 1394, 1293, 1213, 1131, 1071, 1026, 929,741, 681; ¹H NMR (400 MHz, CDCl₃): δ 10.70 (s, 1H), 8.35 (s, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.39–7.35 (m, 2H), 7.34–7.21 (m, 4H), 7.12–7.04 (m, 2H), 6.93 (d, J = 7.6 Hz, 1H), 2.64 (t, J = 6.8 Hz, 2H), 1.72–1.67 (m, 2H), 1.00 (t, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 13.8, 22.9, 32.0, 48.7, 58.7, 110.3, 114.4, 119.1, 122.0, 122.6, 123.3, 126.8, 128.0, 129.4, 138.1, 142.4, 154.9, 155.4, 168.1, 176.7; EIMS (*m*/*z*): 397 (M⁺); Anal. calcd for C₂₃H₁₉N₅O₂: C, 69.51; H, 4.82; N, 17.62; O, 8.05. Found: C, 69.51; H, 4.76; N, 17.65; O, 8.01. 2.3c Entry-5c: 6'-Amino-3'-isopropyl-2-oxo-1'-phenyl-1'Hspiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'-carbonitrile: White solid (84%); M.p. 200–212 °C (exp), 198–200 °C (rep);¹² IR (KBr, v, cm⁻¹): 3360, 3318, 3185, 2921, 2893, 2865, 2210, 1708, 1661, 1586, 1518, 1406, 1301, 1217, 1131, 1075, 931, 742, 610; ¹H NMR (400 MHz, CDCl₃): δ 10.72 (s, 1H), 8.55 (s, 1H), 7.63 (d, J = 6.8 Hz, 1H), 7.38–7.34 (m, 3H), 7.33–7.20 (m, 3H), 7.09–7.03 (m, 2H), 6.92 (d, J = 8.0 Hz, 1H), 3.31–3.23 (m, 1H), 1.31 (d, J = 7.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 21.7, 32.3, 48.8, 58.6, 110.2, 114.3, 119.0, 122.0, 122.5, 123.2, 127.3, 128.0, 129.3, 138.2, 142.5, 154.6, 156.3, 168.1, 177.2; EIMS (*m*/z): 397 (M⁺); Anal. calcd for C₂₃H₁₉N₅O₂: C, 69.51; H, 4.82; N, 17.62; O, 8.05. Found: C, 69.50; H, 4.78; N, 17.66; O, 8.02.

2.3d Entry-5d: 6'-Amino- 5-chloro-3'-methyl-2-oxo-1'phenyl -1'H-spiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'carbonitrile: Light red solid (82%); M.p. 302–304 °C (exp); IR (KBr, v, cm⁻¹): 3352, 3319, 3195, 2201, 1723, 1658, 1591, 1525, 1448, 1395, 1223, 1128, 1074, 965, 908, 757; ¹H NMR (400 MHz, CDCl₃): δ 10.72 (s, 1H), 7.87 (s, 1H), 7.61 (d, J = 7.2 Hz, 1H), 7.36–7.32 (m, 2H), 7.32–7.20 (m, 3H), 7.11–7.05 (m, 2H), 6.91 (d, J = 8.0 Hz, 1H), 1.61 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 13.6, 48.8, 58.8, 110.1, 117.4, 119.0, 122.6, 125.8, 126.6, 127.1, 129.0, 129.3, 130.1, 138.1, 142.5, 147.1, 153.1, 168.0; EIMS (*m*/z): 403 (M⁺); Anal. calcd for C₂₁H₁₄ClN₅O₂: C, 62.46; H, 3.49; Cl, 8.78; N, 17.34; O, 7.92. Found: C, 62.41; H, 3.52; Cl, 8.71; N, 17.30; O, 7.95.

2.3e Entry-5e: Ethyl 6'-Amino-3'-isopropyl-2-oxo-1'-phenyl-1'H-spiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'carboxylate: White solid (81%); M.p. 254-256 °C (exp), 258–259 °C (rep);¹² IR (KBr, v, cm⁻¹): 3379, 3203, 3190, 3024, 2938, 1678, 1628, 1523, 1434, 1376, 1285, 1150, 1072, 955, 783, 746, 688, 627; ¹H NMR (400 MHz, CDCl₃): δ 10.71 (s, 1H), 8.13 (s, 1H), 7.66 (d, J = 7.2 Hz, 1H), 7.38–7.32 (m, 3H), 7.32–7.20 (m, 3H), 7.12–7.07 (m, 2H), 6.93 (d, J = 8.0 Hz, 1H), 4.19 (q, J = 6.4 Hz, 2H), 3.38 (m, 1H), 1.33 (d, J = 8.0 Hz, 6H), 1.04 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 14.0, 22.1, 32.2, 50.0, 62.2, 81.0, 110.2, 114.4, 119.1, 122.6, 123.3, 127.3, 128.0, 129.4, 138.0, 142.4, 153.0, 154.5, 158.0, 165.9, 167.1; EIMS (*m/z*): 444 (M⁺); Anal. calcd for C₂₅H₂₄N₄O₄: C, 67.55; H, 5.44; N, 12.60; O, 14.40. Found: C, 67.51; H, 5.48; N, 12.56; O, 14.44.

2.3f Entry-5f: Ethyl 6'-Amino-2-oxo-1'-phenyl-3'-propyll'H-spiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'-carboxylate: White solid (80%); M.p. 252–254 °C (exp), 256–258 °C (rep);¹² IR (KBr, v, cm⁻¹): 3361, 3258, 3174, 3071, 3029, 2959, 2929, 2869, 2831, 2735, 1689, 1631, 1511, 1467, 1379, 1281, 1165, 1133, 1072, 1039, 935, 785, 760, 747, 682, 617; ¹H NMR (400 MHz, CDCl₃): δ 10.71 (s, 1H), 8.52 (s, 1H), 7.64 (d, *J* = 5.2 Hz, 1H), 7.37–7.34 (m, 2H), 7.25–7.11 (m, 4H), 7.09–7.04 (m, 2H), 6.93 (d, *J* = 8.0 Hz, 1H), 4.08 (q, *J* = 5.2 Hz, 2H), 2.59 (t, *J* = 7.6 Hz, 2H), 1.75 (m, 2H), 1.23 (t, J = 8.8 Hz, 3H), 0.97 (t, J = 8.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 12.4, 13.7, 22.6, 23.1, 49.8, 60.9, 81.4, 110.3, 114.4, 119.1, 122.6, 123.3, 126.8, 128.0, 129.4, 138.1, 142.4, 153.3, 154.9, 158.1, 167.4, 168.3; EIMS (*m*/*z*): 444 (M⁺); Anal. calcd for C₂₅H₂₄N₄O₄: C, 67.55; H, 5.44; N, 12.60; O, 14.40. Found: C, 67.52; H, 5.49; N, 12.63; O, 14.45.

2.3g Entry-5g: 6'-Amino-3'-methyl-2-oxo-1'H-spiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'-carbonitrile:Light red solid (86%); M.p. 287–289 °C (exp), 284–286 °C (rep);⁹ IR (KBr, v, cm⁻¹): 3418, 3385, 3334, 3124, 2684, 2180, 1708, 1678, 1628, 1523, 1464, 1326, 1265, 1150, 1052, 945, 783, 746, 688, 627; ¹H NMR (400 MHz, CDCl₃): δ 12.22 (s, 1H), 10.73 (s, 1H), 7.13–6.92 (m, 3H), 6.91–6.67 (m, 2H), 6.51 (s, 1H), 1.83 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 12.5, 47.1, 58.5, 111.1, 112.5, 116.2, 122.1, 125.9, 127.8, 140.7, 162.7, 167.2, 175.1; EIMS (*m*/*z*): 293 (M⁺); Anal. calcd for C₁₅H₁₁N₅O₂: C, 61.43; H, 3.78; N, 23.88; O, 10.91. Found: C, 61.46; H, 3.82; N, 23.85; O, 10.95.

2.3h Entry-5h: Ethyl 6'-Amino-2-oxo-3'-phenyl-1'Hspiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'-carboxylate: White solid (82%); M.p. 240–242 °C (exp), 242–243 °C (rep);⁹ IR (KBr, v, cm⁻¹): 3482, 3364, 3266, 3174, 3057, 2978, 1715, 1664, 1615, 1476, 1403, 1292, 1145, 1094, 1038, 928, 751; ¹H NMR (400 MHz, CDCl₃): δ 12.17 (s, 1H), 10.33 (s, 1H), 7.42–7.37 (m, 2H), 7.37–7.29 (m, 3H), 7.18–7.09 (m, 3H), 7.01–6.92 (m, 2H), 6.73 (d, J = 7.6 Hz, 1H), 3.62 (q, J = 6.6 Hz, 2H), 0.65 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 13.7, 47.8, 60.5, 81.0, 110.7, 113.7, 124.5, 125.3, 125.8, 126.9, 127.2, 127.9, 128.3, 129.0, 130.3, 139.6, 142.1, 157.4, 161.7, 165.3, 167.2, 167.9; EIMS (*m*/*z*): 402 (M⁺); Anal. calcd for C₂₂H₁₈N₄O₄: C, 65.66; H, 4.51; N, 13.92; O, 15.90. Found: C, 65.63; H, 4.55; N, 13.89; O, 15.94.

2.3i Entry-5i: 6'-Amino-2-oxo-3'-phenyl-1'H-spiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'-carbonitrile:White solid (83%); M.p. 277–279 °C (exp), 280–281 °C (rep);⁹ IR (KBr, v, cm⁻¹): 3384, 3313, 3241, 3143, 2907, 2187, 1705, 1647, 1591, 1496, 1403, 1320, 1211, 1058, 923, 747; ¹H NMR (400 MHz, CDCl₃): δ 12.39 (s, 1H), 10.47 (s, 1H), 7.42–7.27 (m, 2H), 7.27–7.11 (m, 3H), 7.13–7.05 (m, 3H), 6.91–6.89 (m, 2H), 6.82 (d, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 48.1, 59.1, 80.9, 111.5, 114.1, 124.4, 125.3,125.7, 126.9, 127.1, 127.8, 128.2, 129.0, 131.3, 140.2, 143.2, 160.2, 164.2, 168.2, 173.1; EIMS (*m/z*): 355 (M⁺); Anal. calcd for C₂₀H₁₃N₅O₂: C, 67.60; H, 3.69; N, 19.71; O, 9.00. Found: C, 67.63; H, 3.72; N, 19.75; O, 9.03.

2.3j Entry-5j: 3,7,7-Trimethylmethyl-7,8-dihyro-1H-spiro[chromeno[2,3'-c]pyrazole-4,3-indoline]- 2',5(6H)-dione: Yellow solid (84%); M.p. 218–220 °C (exp), 220–222 °C (rep);¹⁶ IR (KBr, v, cm⁻¹): 3370, 3180, 2915, 1719, 1689, 1678, 1615, 1518, 1471, 1340, 1210, 1170, 1117, 1028, 928, 772, 756; ¹H NMR (400 MHz, CDCl₃): δ 12.40 (s, 1H), 10.53 (s, 1H), 7.38–7.37 (m, 1H), 7.36–7.21 (m, 2H), 7.12–7.10 (m, 1H), 2.59–2.20 (m, 2H), 2.19–2.17 (m, 2H), 1.53 (s, 3H), 0.98 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 11.1, 27.8, 34.8, 44.6, 49.7, 51.1, 110.2, 114.4, 119.1, 122.6, 123.3, 128.0, 138.1, 142.4, 161.4, 163.6, 168.4, 200.0; EIMS (*m*/*z*): 349 (M⁺); Anal. calcd for C₂₀H₁₉N₃O₃: C, 68.75; H, 5.48; N, 12.03; O, 13.74; Found: C, 68.71; H, 5.45; N, 12.08; O, 13.77.

2.3k Entry-5k: 5'-bromo-3,7,7- Trimethylmethyl-7,8-dihyro-1H-spiro[chromeno[2,3'-c]pyrazole-4,3-indoline]- 2', 5(6H)-dione: White solid (79%); M.p. 298–299 °C (exp), 301–303 °C (rep);¹⁵ IR (KBr, v, cm⁻¹): 3314, 3231, 2913, 1719, 1652, 1629, 1614, 1589, 1471, 1342, 1276, 1125, 1036, 911, 772, 736; ¹H NMR (400 MHz, CDCl₃): δ 12.27 (s, 1H), 10.19 (s, 1H), 7.49 (s, 1H), 7.26 (d, J = 7.4 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 2.44–2.38 (m, 2H), 2.20–2.18 (m, 2H), 1.62 (s, 3H), 1.19 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 10.6, 26.7, 31.4, 43.1, 48.9, 50.9, 109.4, 110.5, 111.5, 114.2, 124.2, 123.4, 126.6, 138.0, 139.7, 162.2, 199.3; EIMS (*m*/*z*): 427 (M⁺); Anal. calcd for C₂₀H₁₈. BrN₃O₃: C, 56.09; H, 4.24; Br, 18.66; N, 9.81; O, 11.21; Found: C, 56.12; H, 4.21; Br, 18.61; N, 9.85; O, 11.26.

2.31 Entry-51: 5'-chloro-3,7,7- Trimethylmethyl-7,8-dihyrro-1H-spiro[chromeno[2,3'-c]pyrazole-4,3-indoline]-2',

5(6*H*)-dione: Cream solid (81%); M.p. 212–214 °C (exp), 215–217 °C (rep);¹⁸ IR (KBr, ν, cm⁻¹): 3209, 3112, 2910, 1709,1689, 1656,1612, 1510, 1469, 1339, 1208, 1164, 1115, 1028, 908, 768, 746; ¹H NMR (400 MHz, CDCl₃): δ 12.38 (s, 1H), 10.06 (s, 1H), 7.73 (s, 1H), 7.34 (d, *J* = 5.6, 1H), 6.96 (d, *J* = 7.2, 1H), 2.11 (s, 2H), 2.09 (s, 2H), 1.50 (s, 3H), 1.15 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 10.9, 27.1, 31.6, 43.4, 49.1, 51.0, 110.3, 110.5, 114,4, 124.9, 125.9, 127.3, 138.3, 140.0, 163.7, 200.0; EIMS (*m*/*z*): 383 (M⁺); Anal. calcd for C₂₀H₁₈ClN₃O₃: C, 62.58; H, 4.73; Cl, 9.24; N, 10.95; O, 12.50; Found: C, 62.52; H, 4.69; Cl, 9.21; N, 10.99; O, 12.53.

2.3m Entry-5m: 3methyl-7,8-dihyro-1H-spiro[chromeno[2,3'-c]pyrazole-4,3-indoline]-2',5(6H)-dione:-White solid (82%); M.p. 296–298 °C (exp), 301–302 °C (rep);¹⁵ IR (KBr, v, cm⁻¹): 3331, 3233, 2917, 1719, 1645, 1610, 1601, 1520, 1471, 1344, 1205, 1173, 1114, 1028, 817, 771, 709; ¹H NMR (400 MHz, CDCl₃): δ 12.45 (s, 1H), 10.49 (s, 1H), 7.66 (s, 1H), 7.64-7.21 (m, 3H), 2.78-2.68 (m, 2H), 2.10–2.07 (m, 5H), 1.69–1.64 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 12.6, 20.1, 28.0, 36.3, 50.1, 110.2, 113.1, 114.4, 123.3, 126.7, 128.0, 138.0, 142.5, 162.1, 163.5, 167.2, 199.4; EIMS (*m/z*): 321 (M⁺); Anal. calcd for C₁₈H₁₅N₃O₃: C, 67.28; H, 4.71; N, 13.08; O, 14.94; Found: C, 67.25; H, 4.74; N, 13.03; O, 14.98.

2.3n Entry-5n: 5'- bromo-3-methyl-7,8-dihyro-1H-spiro[chromeno[2,3'-c]pyrazole-4,3-indoline]- 2', 5(6H)-dione: Yellow solid (83%); M.p. 308–310 °C (exp); IR (KBr, v, cm⁻¹): 3301, 3213, 2907, 1713, 1641, 1603, 1591, 1511, 1453, 1324, 1201, 1153, 1104, 1013, 809, 763, 701; ¹H NMR (400 MHz, CDCl₃): δ 12.59 (s, 1H), 10.49 (s, 1H), 7.78 (s, 1H), 7.29 (d, *J* = 6.8 Hz, 1H), 6.84 (d, *J* = 8.4 Hz, 1H), 2.63 (t, *J* = 6.0 Hz, 2H), 2.12–2.06 (m, 5H), 1.78–1.72 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 12.1, 21.9, 27.1, 36.0, 49.6, 110.3, 114.4, 119.1, 125.9, 129.1, 129.4, 134.3, 138.2, 141.9, 161.0, 163.7, 168.1, 198.9; EIMS (m/z): 399 (M⁺); Anal. calcd for C₁₈H₁₄. BrN₃O₃: C, 54.02; H, 3.53; Br, 19.96; N, 10.50; O, 11.99; Found: C, 54.08; H, 3.53; Br, 19.91; N, 10.45; O, 11.96.

2.30 Entry-50: 3,7,7- trimethyl-1-phenyl-7,8-dihvro-1Hspiro[chromeno[2,3' -c]pyrazole-4,3-indoline]-2',5(6H)dione: Cream solid (81%); M.p. 243-245 °C (exp), 238–240 °C (rep);¹⁷ IR (KBr, v, cm⁻¹): 3138, 2881, 1701, 1641, 1601, 1589, 1508, 1463, 1326, 1201, 1171, 1115, 1025, 815, 769, 709, 681, 512; ¹H NMR (400 MHz, CDCl₃): δ 10.61 (s, 1H), 7.71–7.59 (m, 3H), 7.57–7.48 (m, 2H), 7.45-7.38 (m, 4H), 2.49-2.45 (m, 2H), 2.28-2.19 (m, 2H), 1.63 (s, 3H), 1.07 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 12.1, 25.7, 26.8, 31.7, 40.9, 46.4, 49.3, 98.8, 107.5, 111.2, 119.7, 121.3, 122.4, 126.7, 127.9, 128.5, 132.9, 135.6, 141.2, 144.0, 143.7, 165.3, 177.4, 195.2, 195.2, 196.0; EIMS (m/z): 425 (M⁺); Anal. calcd for C₂₆H₂₃N₃O₃: C, 73.35; H, 5.40; N, 9.82; O, 11.28; Found: C, 73.31; H, 5.44; N, 9.85; O, 11.22.

2.3p Entry-5p: 5'- bromo-3,7,7-trimethyl-1-phenyl-7,8-dihyro-1H-spiro[chromeno[2,3'-c]pyrazole-4,3-indoline]-

2',5(6H)-dione: Off white solid (80%); M.p. 266–268 °C (exp), 272–274 °C (rep);¹⁵ IR (KBr, v, cm⁻¹): 3229, 2918, 1717, 1641, 1605, 1591, 1518, 1471, 1341, 1205, 1175, 1028, 820, 771, 683, 519; ¹H NMR (400 MHz, CDCl₃): δ 10.76 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.43 (t, J = 7.4 Hz, 2H), 7.29–7.12 (m, 3H), 7.09 (s, 1H), 6.93 (d, J = 7.6 Hz, 1H), 2.42 (s, 2H), 2.35 (s, 2H), 1.53 (s, 3H), 1.17 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 12.0, 25.5, 26.7, 31.7, 40.9, 46.4, 50.0, 98.1, 107.1, 110.7, 118.2, 121.0, 121.9, 126.1, 127.6, 128.1, 131.2, 134.4, 140.1, 143.2, 143.6, 165.0, 176.8, 186.1, 194.9, 195.7; EIMS (m/z): 503 (M⁺); Anal. calcd for C₂₆H₂₂BrN₃O₃: C, 61.91; H, 4.40; Br, 15.84; N, 8.36; O, 9.52; Found: C, 61.94; H, 4.43; Br, 15.81; N, 8.31; O, 9.56.

3-methyl-1-phenyl-7,8-dihyro-1H-spir-Entry-5q: 2.3q o[chromeno[2,3'-c]pvrazole-4.3-indoline]-2', 5(6H)-dione: Off white solid (82%); M.p. 293-295 °C (exp), 296-298 °C (rep);¹⁵ IR (KBr, v, cm⁻¹): 3193, 1714, 1671, 1643, 1617, 1598, 1515, 1469, 1351, 1331, 1301, 1179, 1121, 751, 681, 619; ¹H NMR (400 MHz, CDCl₃): δ 10.51 (s, 1H), 7.63-7.51 (m, 3H), 7.39-7.17 (m, 4H), 7.12-6.93 (m, 2H), 2.8–2.7 (t, J = 6.4 Hz, 2H), 2.81–2.78 (t, J = 6.4 Hz, 2H), 2.13-2.05 (m, 5H), 1.62-1.57 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 11.7, 19.8, 26.3, 35.9, 46.7, 97.6, 108.7, 112.0, 119.7, 120.6, 121.3, 126.1, 127.1, 128.7, 133.7, 139.2, 141.1, 143.0, 163.2, 175,8, 183.5, 191.6, 193.7, 194.2; EIMS (m/z): 397 (M⁺); Anal. calcd for C₂₄H₁₉N₃O₃: C, 72.53; H, 4.82; N, 10.60; O, 12.08; Found: C, 72.50; H, 4.85; N, 10.65; O, 12.03.

2.3r Entry-5r: 5'- bromo-3-methyl-1-phenyl-7,8-dihyro-1Hspiro[chromeno[2,3'-c]pyrazole-4,3-indoline]-2',5(6H)-

dione: White solid (77%); M.p. 303–305 °C (exp), 307–309 °C (rep);¹⁷ IR (KBr, ν , cm⁻¹): 3081, 2939, 1688, 1649, 1590, 1592, 1521, 1468, 1398, 1265, 1118, 748, 677, 609; ¹H NMR (400 MHz, CDCl₃): δ 10.62 (s, 1H), 7.59–7.34



Table 2. One pot synthesis of spiro[indoline-3,4'-pyrano[2,3-c]pyrazole] derivatives (**5a-i**)^a.

^aReaction condition: β -ketoesters (1 mmol), hydrazines (1 mmol), isatins (1 mmol) and active methylene compounds (1 mmol), 5 mL of DES (Urea:ChCl in 2:1 ratio), stirring for 10 min.

(m, 3H), 7.29–7.15 (m, 3H), 7.03–6.95 (m, 2H), 2.77–2.64 (t, J = 6.4 Hz, 2H), 2.22–2.17 (m, 5H), 1.73–1.67 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 11.9, 25.2, 26.7, 31.6, 46.2, 49.6, 97.1, 111.0, 111.4, 112.5, 119.7, 125.4, 125.9, 128.7, 130.3, 135.8, 136.5, 140.7, 143.9, 144.6, 165.5, 172.3, 189.9, 193.3; EIMS (m/z): 475 (M⁺); Anal. calcd for C₂₄H₁₈. BrN₃O₃: C, 60.52; H, 3.81; Br, 16.77, N, 8.82; O, 10.08; Found: C, 60.55; H, 3.77; Br, 16.71, N, 8.79; O, 10.12.

3. Results and Discussion

At the very onset of this work, we started the one-pot four-component reaction using ethylacetoacetate **1a**, phenyl hydrazine **2a**, isatin **3a** and malonitrile **4a** in freshly prepared deep eutectic solvent (Figure 2) of urea:choline chloride (10 mol%, 2:1 ratio of urea:choline chloride) at room temperature. To our delight, the expected product i.e., spiro[indoline-3,4'pyrano[2,3-c]pyrazole] derivatives **5a** was isolated with 85% yield. The overall reaction time for complete transformation took only 5 min as monitored by TLC. (entry 1, Table 1). Then, to check the optimized condition, we performed the reaction in different conditions. We increased the reaction duration from 5 min to 10 min, the yield of the isolated product increases to 90% (entry 2, Table 1). On further increasing the reaction duration up to 30 min, the yield of the product remains constant (entry 3,



Table 3. One pot via four component synthesis of spiro[chromeno[2,3-c]pyrazole-4,3'-indoline]-diones (5j-r).

^aReaction condition: β -ketoesters (1 mmol), hydrazines (1 mmol), isatins (1 mmol) and cyclic active methylene compounds (1 mmol), 5 mL of DES (Urea:ChCl in 2:1 ratio), stirring for 10 mins.

Table 1). Again, the effect of change in temperature was observed when the reaction temperature was enhanced to 50 °C and 60 °C, the percentage of the isolated product remains as usual of 90% (entries 4 and 5, Table 1). Also, we performed the reaction in ice-bath condition i.e., 4 °C, the isolated yield was 80% after stirring for 30 min (entry 6, Table 1). The efficiency of other DESs was also determined under optimized temperature. When the reaction was performed using various freshly prepared DESs namely malonic acid:ChCl, oxalic acid:ChCl, PTSA:ChCl, glycerin:ChCl (entries 7–11, Table 1), the reaction did not improve the yield of the product. This

indicates that the DES components participate in the reaction but not to the extent as that of urea:ChCl, which behaves as a base for abstracting protons from active methylene compounds and participate in solvating all the components and intermediates of this procedure efficiently. Lastly, when the reaction was performed under solvent-free at room temperature for 24 h, the reaction mixture did not proceed as indicated in the TLC. Thus, the optimized condition for synthesis of spirooxindole derivative starting from ethylacetoacetate **1a**, phenyl hydrazine **2a**, isatin **3a** and malonitrile **4a** required DES prepared from urea:ChCl (2:1 ratio of choline chloride: urea) as

solvent and stirring the reaction mixture at room temperature for just 10 min (**5a**, 85%).

After optimization of the reaction conditions, we turned our attention to fully characterize the four component product **5a**. From ¹H NMR spectrum of **5a**, one singlet peak at $\delta = 10.7$ ppm, a multiplet peak at $\delta = 6.92-7.89$ ppm and one singlet peak at $\delta = 1.67$ ppm indicated the presence of NH proton, aromatic protons and methyl protons, respectively. From ¹³C NMR spectrum, the presence of spirocyclic carbon was observed at 48.8 ppm, one carbonyl and one nitrile peaks were observed at 177.6 and 114.4 ppm, respectively and the peak at 13.6 ppm corresponds to lone methyl carbon.

Based on the optimized reaction conditions (entry 2, Table 1), we wish to extend the scope of this reaction using various types of substrates of each of the four components. A series of spiro[indoline-3,4'-pyr-ano[2,3-c]pyrazole] derivatives **5a-I**, were obtained in good yields (Table 2) and these reactions were found

to proceed very cleanly at room temperature and no side reaction products were observed. The products were tolerant of a different set of β -ketoesters **1a-d**, hydrazines **2a-b**, isatins **3a-b** and active methylene compounds **4a-b**. For instance, the treatment of β ketoesters **1b** and **1c** bearing n-propyl and isopropyl groups with phenylhydrazine **2a**, isatin **3a** and malononitrile **4a** provided desired products **5b** and **5c** in 83% and 84% yield, respectively.

Encouraged by this success, the scope of this multicomponent reaction was further investigated by changing the aliphatic active methylene compounds to cyclic active methylene compounds. Under the same reaction condition, target compounds **5j-r** (Table 3) were obtained in good yields by treating β -ketoesters **1a**, phenylhydrazines **2a-b**, isatins **3a-b** with 5,5dimethylcyclohexane-1,3-dione **4c** and cyclohexane-1,3-dione **4d**. From the above observations, it was worthy to mention that DES function as both a promoter as well as a reaction media, which results in the



Scheme 2. Probable mechanism of spirooxindole derivatives synthesis.

successive condensation forming the desired target products **5a-r**.

The recyclability of solvent is an important factor affecting the economics of practical applications of DES. The model reaction of ethyl acetoacetate **1a**, phenylhydrazine **2a**, isatin **3a** and malononitrile **4a** was selected to investigate this issue under the optimal conditions. After completion of the reaction, the reaction mixture, including DES and products, was dissolved in water and the crude product was obtained by extraction with EtOAc. The DES was recovered from the aqueous phase by evaporation at 80 °C under vacuum and was recycled for the next reaction. As demonstrated in Figure 3, the DES could be recycled and reused up to four times with only a slight decrease in catalytic activity.

A plausible reaction mechanism for the synthesis of spiro[indoline-3,4'-pyrano[2,3-c]pyrazole] derivative 5a and 5i is shown in Scheme 2. The reaction begins with the activation of carbonyl group of ethylacetoacetate **1a** by the NH₂ group of DES (urea: choline chloride mixture), results in stronger H-bond formation which enhances the electrophilic character of carbonyl carbon of compound 1a. Compound 1a undergoes a condensation reaction with phenylhydrazine 2a to form intermediate I, pyrazol-5-one derivatives. A Knoevenagel condensation between isatin 3 and intermediate I yield an adduct II. Finally, Michael addition reaction occurs between adduct II and malononitrile 4a, undergoes intramolecular cyclisation followed by tautomerization to form target product 5a and similarly with cyclic compound 4c, the product 5j was obtained in good yield.

4. Conclusions

In conclusion, an efficient, clean, atom-economical and green method for the preparation of spirooxindoles using DES based on choline chloride is reported. The DES was found to play as a good reaction medium. This method offers several advantages such as operational simplicity, good to excellent product yields, and avoids the use of expensive or sensitive catalyst. Further, this procedure is highly sustainable because of the employment of readily available and biodegradable deep eutectic solvent.

Supplementary Information (SI)

¹H NMR and ¹³CNMR data is available at www.ias.ac.in/ chemsci.

Acknowledgements

Financial support from the CSIR [No. 02(0251)/15/EMR-II] and DST [No. EMR/2014/00033], Government of India, are gratefully appreciated.

References

- 1. Vicente R 2011 Recent advances in indole syntheses: New routes for a classic target *Org. Biomol. Chem.* **9** 6469
- Singh T P and Singh O M 2018 Recent progress in biological activities of indole and indole alkaloids *Mini-Rev. Med. Chem.* 18 9
- 3. Galliford C V and Scheidt K A 2007 Pyrrolidinylspirooxindole natural products as inspirations for the development of potential therapeutic agents *Angew*. *Chem. Int. Ed.* **46** 8748
- 4. Cheng D, Ishihara Y, Tan B and Barbas C F III 2014 Organocatalytic asymmetric assembly reactions synthesis of spirooxindoles *via* organocascade strategies *ACS Catal.* **4** 743
- Ding K, Lu Y, Nikolovska-Coleska Z, Qui S, Ding Y, Gao W, Stuckey J, Krajewski K, Roller P P, Tomita Y, Parrish D A, Deschams J R and Wang S 2005 Structurebased design of potent non-peptide MDM2 inhibitors *J. Am. Chem. Soc.* **127** 10130
- 6. Tian Y, Nam S, Liu L, Yakushijin F, Yakushijin K, Buettner R, Liang W, Yang F, Ma Y, Horne D and Jove R 2012 A metagenomic approach to characterization of the vaginal microbiome signature in pregnancy *PLoS One* **7** 1
- 7. Rottmann M, McNamara C, Yeung B K S, Lee M C S, Zou B, Russell B, Seitz P, Plouffe D M, Dharia N V, Tan J, Cohen S B, Spencer K R, González-Páez G E, Lakshminarayana S B, Goh A, Sueanarusk R, Jegla T, Schmitt E K, Beck H P, Brun R, Nosten F, Renia L, Dartois V, Keller T H, Fidock D A, Winzeler E A and Diagana T T 2010 Spiroindolones, a potent compound class for the treatment of malaria *Science* **329** 1175
- Zou B, Yap P, Sonntag L S, Leong S Y, Yeung B K S and Keller T H 2012 Mechanistic study of the spiroindolones: a new class of antimalarials *Molecules* 17 10131
- 9. Robertson D W, Krushinski J H, Pollock G D, Wilson H, Kauffman R F and Hayes J S 1987 Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6- tetrahydro-6-oxo-3-pyridazinyl)-spiro [cycloalkane-1, 3'-[3H]indol]-2'(1'H)-ones *J. Med. Chem.* **30** 824
- 10. Tayade Y A, Padvi S A, Wagh Y B and Dalal D S 2015 β -cyclodextrin as a supramolecular catalyst for the synthesis of dihydropyrano[2,3-c]pyrazole and spiro[indoline-3, 4'-pyrano[2,3-c] pyrazole] in aqueous medium *Tetrahedron Lett.* **56** 2441
- 11. Zou Y, Hu Y, Liu H and Shi D 2012 Rpid and efficient ultrasound-assisted method for the combinatorial synthesis of spiro[indoline-3,4'-pyrano[2,3-c]pyrazole derivatives ACS Comb. Sci. 14 38

- 12. Liu X, Xu X, Wang X, Yang W, Qian Q, Zhang M, Song L, Deng H and Shao M 2013 A facile and convenient way to functionalized trifluoro methylated spirocyclic[indole-3,4-pyrano[2,3-c]pyrazole derivatives *Tetrahedron Lett.* 54 4451
- Yu J, Zhou Y, Shen, Mao W, Chen K and Song Q 2013 Novel and efficient one-pot synthesis of spiro[indoline-3,4'pyrano[2,3-c]pyrazole]derivatives catalyzed by L-proline in aqueous medium *J. Chem. Res.* 37 365
- Bodhak C, Kundu A and Pramanik A 2015 ZrO₂ nanoparticles as a reusable solid dual acid-base catalyst for facile one-pot synthesis of multi-functionalised spirooxindole derivatives under solvent free condition *RSC Adv.* 5 85202
- 15. Feng J, Ablajan K and Sali A 2014 4-Dimethylaminopyridine-catalyzed multi-component one-pot reactions for the convenient synthesis of spiro[indoline-3,4'-pyrano[2,3-c]pyrazole]derivatives *Tetrahedron Lett.* **70** 484
- Rai P, Srivastava M and Singh J 2014 Chitosan/ionic liquid forms a reusable catalyst system used for the synthesis of highly functionalized spiro derivatives *New J. Chem.* 38 3181
- 17. Liu T, Li C-B, Yu Y-Q and Xu D-Z 2017 An efficient four-component reaction for the rapid synthesis of highly functionalized pyrano[2,3-c]pyrazoles catalyzed by [Dabco-H][AcO] ionic liquid under mild condition *ChemistrySelect* **2** 2917
- Shrestha R, Sharma K, Lee Y R and Wee Y J 2016 Cerium oxide-catalyzed multicomponent condensation approach to spirooxindoles in water *Mol. Divers.* 20 847
- 19. Mukherjee P, Paul S and Das A R 2015 Expeditious synthesis of functionalized tricyclic 4-spiro pyrano[2,3-c]pyrazoles in aqueous medium using dodecylbenzene-sulphonic acid as a Bronsted acid-surfactant-combined catalyst *New J. Chem.* **39** 9480
- 20. Alemi-Tameh F, Safaei-Ghomi F, Mahmoudi-Hashemi M and Shahbazi-Alavi H 2016 One-pot multicomponent reaction synthesis of spirooxindoles promoted by guanidine-functionalized magnetic Fe₃O₄ nanoparticles *RSC Adv.* 6 74802
- Hojati S F, Amiri A, Mohamadi S and MoeiniEghbali N 2018 Novel organometallic nanomagnetic catalyst for multicomponent synthesis of spiroindoline derivatives *Res. Chem. Intermed.* 44 2275
- 22. Ziarani G M, Moradi R, Lashgari N, Badiei A and Soorki A A 2018 One-pot synthesis of spiro[chromeno[2,3-c]pyrazole-4,3'-indoline]-diones using sulfonic acid functionalized nanoporous silica SBA-Rr-

SO₃H and study of their antimicrobial properties *Polycyl. Aromat. Comp.* **38** 66

- 23. Safari J and Ahmadzadeh M 2017 Zwitterionic sulfamic acid functionalized nanoclay: A novel nanocatalyst for the synthesis of dihydropyrano[2,3-c]pyrazoles and spiro[indoline-3,4 '-pyrano[2,3-c]pyrazole] derivatives *J. Taiwan Inst. Chem. Eng.* **74** 14
- 24. Alemi-Tameh F, Safaei-Ghomi J, Mahmoudi-Hashemi M and Teymuri R 2016 A comparative study on the catalytic activity of Fe₃O₄@SiO₂-SO₃H and Fe₃O₄@-SiO₂-NH₂ nanoparticles for the synthesis of spiro[chromeno[2,3-c]pyrazole-4,3'-indoline]-diones under mild conditions *Res. Chem. Intermed.* 42 6391
- 25. Dai Y, Van Spronsen J, Witkamp G J, Verpoorte R and Choi Y H 2013 Natural deep eutectic solvents as new potential media for green technology *Anal. Chem. Acta* **766** 61
- 26. Abbott A P, Capper G, Davies D L, Rasheed R K and Tambyrajah V 2003 Novel solvent properties of choline chloride/urea mixtures *Chem. Commun.* **70**
- 27. Handy S and Wright M 2014 An acid-free Pictet-Spengler reaction using deep eutectic solvents (DES) *Tetrahedron Lett.* **55** 3440
- 28. Phadtare S B, Jarag K J and Shankarling G S 2013 Greener protocol for one pot synthesis of coumarin styeyl dyes *Dyes Pigm.* **97** 105
- 29. Gorke J T, Srienc F and Kazlauskas R J 2008 Hydrolase-catalyzed biotransformations in deep eutectic solvents *Chem. Commun.* **1235**
- 30. Gore S, Baskaran S and Koenig B 2011 Efficient synthesis of 3,4-dihydropyrimidin-2-ones in low melting tartaric acid-urea mixtures *Green Chem.* **13** 1009
- 31. Singh T P, Devi T J, Singh N P and Singh O M 2018 GFP chromophores from L-phenylanaline: Synthesis, photophysical and thermal properties *Chem. Select* **3** 6596
- Singh T P and Singh O M 2016 One pot synthesis of 1-substituted tetrahydro-β-carbolines by Bischler-Napieralski cyclization J. Chem. Sci. 128 565
- 33. Singh T P and Shunmugam R 2016 PCl₃-mediated synthesis of green/cyan fluorescent protein chromophores using amino acids *New J. Chem.* **4** 3024
- 34. Singh T P, Bhattarcharya S and Singh O M 2013 Indium/TFA-catalyzed synthesis of tetracyclic [6,5,5,6]indole ring via a tendem cycloannulation of β -oxodithioester with tryptamine *Org. Lett.* **15** 1974
- 35. Yang H and Reddy R G 2014 Electrochemical deposition of zinc from zinc oxide in 2:1 urea/choline chloride ionic liquid *Electrochim. Acta* 147 513